News & events Upcoming events Webinar: Possible applications for novel CSF biomarkers Dec 15, 2021 - Dec 15, 2021 Webinar , Belgium More info and meet us there AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's diseases and related neurological disorders Mar 15, 2022 - Mar 20, 2022 Barcelona , Spain More info and meet us there 19th CACLP (China Association of Clinical Laboratory Practice) Expo Mar 27, 2022 - Mar 29, 2022 Nanchang , China More info and meet us there See all upcoming events Latest news Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Nov 19, 2021 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution Oct 28, 2021 H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Aug 18, 2021 Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Jun 16, 2021 Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more Statement on the impact of coronavirus disease Covid-19 on our operations Jan 19, 2021 The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Dec 8, 2020 Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more Load More
Webinar: Possible applications for novel CSF biomarkers Dec 15, 2021 - Dec 15, 2021 Webinar , Belgium More info and meet us there
AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's diseases and related neurological disorders Mar 15, 2022 - Mar 20, 2022 Barcelona , Spain More info and meet us there
19th CACLP (China Association of Clinical Laboratory Practice) Expo Mar 27, 2022 - Mar 29, 2022 Nanchang , China More info and meet us there
Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Nov 19, 2021 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more
Fujirebio Europe receives translational research funding from Alzheimer’s Drug Discovery Foundation for development of a fully automated plasma pTau181 testing solution Oct 28, 2021 H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator... Read more
Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 S-IgG assay Aug 18, 2021 Fujirebio Europe announces the CE marking of the Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated... Read more
Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva Jun 16, 2021 Gent, Belgium – June 16, 2021: Fujirebio Europe today announced the commercial launch of iAMP COVID-19 SANO (Saliva And Nasopharyngeal... Read more
Statement on the impact of coronavirus disease Covid-19 on our operations Jan 19, 2021 The novel coronavirus disease Covid-19 first reported in late 2019 has spread worldwide. At Fujirebio Europe’s Belgian facilities, we are... Read more
OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Dec 8, 2020 Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more
